# US 2003/0216550 A1 · Modified chitin binding domain and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0216550 A1
- Document ID: US20030216550A1
- Status: Published application
- Kind: A1
- Application number: 10/375,913
- Filed: 2003-02-26
- Published: 2003-11-20
- Earliest claimed: 2002-02-28
- Assignees: New England Biolabs, Inc.
- Inventors: Ming-Qun Xu; Sebastien M. Ferrandon; Christopher H. Taron; Paul A. Colussi
- Web page: https://patentgrep.com/patent/US20030216550A1

## CPC

- C12N 15/80: for fungi
- C12N 9/2442: {Chitinase (3.2.1.14)}
- C12Y 302/01014: Chitinase (3.2.1.14)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

Compositions and methods are provided for reversibly binding chitin binding domain (CBD) to a chitin or equivalent substrate under non denaturing conditions. CBD is modified preferably by a mutation to achieve this change in properties. In one embodiment, an aromatic amino acid residue located in the binding cleft of the CBD was altered resulting in reversible binding affinity for substrate in select conditions. Creating a modified CBD with an altered binding affinity for substrate provides new uses for CBD not previously possible with unmodified CBD which binds irreversibly to chitin.

## Claims

### Claim 1

A protein comprising: a chitin binding domain (CBD) capable of reversibly binding a chitin substrate under a selected non-denaturing condition.

### Claim 2 (depends on 1)

A protein according to claim 1, wherein the CBD has one or more mutated amino acids.

### Claim 3 (depends on 2)

A protein according to claim 2, wherein the mutated amino acid is an aromatic amino acid.

### Claim 4 (depends on 2)

A protein according to claim 2, wherein the mutated amino acid is positioned within a binding cleft of the CBD.

### Claim 5 (depends on 3)

A protein according to claim 3, wherein the amino acid comprises a tryptophan.

### Claim 6 (depends on 5)

A protein according to claim 5, wherein the tryptophan corresponds to tryptophan 687 of B. circulans chitinase A1.

### Claim 7 (depends on 1)

A protein according to claim 1, wherein the non-denaturing conditions are selected from changes in any of: ionic conditions; pH; detergent concentration, or antagonist or agonist concentration.

### Claim 8 (depends on 1)

A protein according to claim 1, wherein the non-denaturing conditions comprise a change in ionic conditions.

### Claim 9 (depends on 8)

A protein according to claim 8, wherein the change in ionic conditions comprise a reduced salt concentration.

### Claim 10

A method of obtaining a chitin binding domain (CBD) capable of reversibly binding to a chitin substrate under non-denaturing conditions, the method comprising:
(a) modifying at least one amino acid within the CBD;
(b) selecting the modified CBD according to its binding to the chitin substrate; and
(c) determining whether the modified CBD is capable of reversibly binding chitin under altered conditions.

### Claim 11 (depends on 10)

A method according to claim 10, wherein modifying at least one amino acid within the CBD, further comprises:
mutating a portion of a DNA sequence encoding the CBD and expressing the DNA in a host cell or by in vitro translation.

### Claim 12 (depends on 11)

A method according to claim 11, wherein mutating a portion of the DNA sequence, further comprises:
substituting with an oligonucleotide, a portion of the DNA sequence encoding the CBD, the oligonucleotide differing from the substituted portion by a mutation at a target site.

### Claim 13 (depends on 12)

A method according to claim 12, wherein the target site is a tryptophan and the mutation is a phenylalanine substitution of the tryptophan.

### Claim 14 (depends on 10)

A method according to claim 10, wherein the selected condition comprises altering ionic conditions.

### Claim 15 (depends on 10)

A method according to claim 10, wherein the selected condition comprises changing NaCl molarity.

### Claim 16

A method for producing and purifying a target protein molecule comprising:
(a) constructing a DNA expression vector which expresses a hybrid polypeptide in a transformed host cell, the hybrid polypeptide comprising the target protein molecule and a modified chitin binding domain having a specific and reversible affinity for a substrate which binds to the chitin binding domain;
(b) introducing the expression vector into an appropriate host cell and expressing the hybrid polypeptide;
(c) contacting the hybrid polypeptide produced by the transformed cell with the substrate to which the CBD binds; and
(d) recovering the hybrid polypeptide.

### Claim 17 (depends on 16)

A method according to claim 16, wherein recovering the hybrid polypeptide comprises altering the ionic conditions.

### Claim 18 (depends on 16)

The method of claim 16, wherein recovery of the hybrid polypeptide further comprises:
contacting the bound hybrid polypeptide with a substance which displaces the hybrid polypeptide.

### Claim 19 (depends on 17)

A method according to claim 17, wherein the altered ionic condition is a reduction in NaCl molarity.

### Claim 20 (depends on 16)

A method according to claim 16, wherein the substrate is chitin.

### Claim 21

A method for purifying a chitin binding domain-target molecule conjugate from a mixture of molecules in a preparation comprising:
(a) adding to the preparation, a substrate having a specific and reversible affinity for CBD so as to permit binding and immobilizing of the conjugate to the substrate;
(b) removing the bound conjugate from the mixture into a buffer; and
(c) altering the ionic conditions in the buffer so as to elute the conjugate from the substrate into the buffer to obtain the purified conjugate.

### Claim 22 (depends on 21)

A method according to claim 21, wherein the altered ionic conditions comprise a change in NaCl molarity.

### Claim 23 (depends on 21)

A method according to claim 21, wherein the substrate is chitin.

### Claim 24

A kit for purifying a recombinant protein, comprising:
(a) a plasmid, the plasmid containing a DNA sequence encoding a mutant CBD which is capable of reversibly binding a chitin matrix and an insertion site for inserting the DNA sequence encoding the recombinant protein; and
(b) the chitin matrix for binding the fusion protein; and
optionally a buffer for eluting the fusion protein from the chitin matrix.

### Claim 25

A fusion vector for constructing an expression vector which expresses a modified chitin binding domain (CBD) fused to a protein molecule to be purified, comprising:
a DNA fragment coding for the modified chitin binding domain or portion thereof, having a specific and reversible affinity for a substrate which binds to the chitin binding protein.

### Claim 26

A DNA expression vector for producing a purified protein molecule, which upon expression produces a chitin binding domain fused to the protein molecule, comprising:
(a) a first DNA fragment coding for the chitin binding domain (CBD) or portion thereof having a specific and reversible affinity for substrate which binds to the chitin binding protein; and
(b) a second DNA fragment coding for the protein molecule to be purified.

### Claim 27 (depends on 25, 26)

A method according to claims 25 or 26 wherein the substrate is chitin.

### Claim 28

A vector comprising a sequence for a mutant CBD and optionally an insertion site for placing a sequence encoding a recombinant protein within or adjacent to the CBD sequence.

### Claim 29 (depends on 28)

A vector according to claim 28, wherein the mutation is at Try 687

### Claim 30 (depends on 25, 26, 28)

A host cell for making a fusion protein, comprising: a vector according to claims 25, 26 or 28.
